Cochlear Limited
Recent
price
P/E
ratio
div
yld
3.14%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cochlear Limited (ASX:COH) develops, manufactures and markets implantable hearing solutions worldwide, including cochlear implants, bone conduction systems and associated sound processors; the company provides the Cochlear Nucleus System, Baha System, Osia System, Kanso 3 Sound Processor, sound processor upgrades, accessories and clinical support software such as Custom Sound Pro Fitting Software and Nucleus SmartNav System. Cochlear holds approximately 60% global market share in cochlear implants and advances bimodal hearing solutions combining implants with hearing aids. Founded in 1981 and headquartered at Macquarie University in Sydney, Australia, the company operates across more than 180 countries with key revenue contributions from the Americas (49%), Europe, Middle East and Africa (35%), and Asia-Pacific (16%), employing over 5,000 people. Recent developments include the May 2024 acquisition of Oticon Medical's cochlear implant business from Demant for A$170 million, expanding its implant portfolio and customer base by over 20,000 patients; the July 2025 launch of the world's first smart cochlear implant, the Nucleus Nexa System, featuring upgradeable firmware, machine learning and AI integration; and the March 2025 expansion of its R&D partnership with GN through the Smart Hearing Alliance to accelerate AI, deep neural networks and connectivity innovations for integrated hearing solutions.
Company News
CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY) Stock Now Rated “Hold” by Sell-Side Analysts
Cochlear to defend shareholder class action over 2026 profit forecast
Cochlear Reaches More Than 1 Million Hours of Patient Experience Across Its Fully Implantable Hearing Technology Research Program
Cochlear Reaches More Than 1 Million Hours of Patient Experience Across Its Fully Implantable Hearing Technology Research Program
Cochlear (OTCMKTS:CHEOF) Trading 6.5% Higher – Here’s What Happened
Cochlear Limited (CHEOY) Q4 2026 Earnings Call Transcript
CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY) Sees Significant Drop in Short Interest
Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
Don't Miss the Moments That Matter This Summer: Hearing Experts and Cochlear Encourage People to Check Their Hearing Health
Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants
Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant
MED-EL USA Presents Real World Clinical Insights to Support Tailored Hearing Solutions at the 2026 American Cochlear Implant Association Meeting
Cochlear Limited (CHEOY) Q3 2026 Sales/Trading Call Transcript
Australia's Cochlear crashes 40% after flagging weak demand and Mideast war impact
Head-To-Head Survey: DocGo (NASDAQ:DCGO) vs. CochLear (OTCMKTS:CHEOY)
Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant
Cochlear Limited (OTCMKTS:CHEOF) Short Interest Update
Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant
CochLear (OTCMKTS:CHEOY) and Sonic Healthcare (OTCMKTS:SKHHY) Financial Review